Viewing Study NCT05589857


Ignite Creation Date: 2025-12-24 @ 6:37 PM
Ignite Modification Date: 2025-12-29 @ 6:13 AM
Study NCT ID: NCT05589857
Status: WITHDRAWN
Last Update Posted: 2024-10-23
First Post: 2022-10-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Overview

Official Title: A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
Status: WITHDRAWN
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: No Patients Enrolles
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Tto learn if playing an augmented reality game called SpellBound can reduce pain and the need for opioids in young patients following surgery.
Detailed Description: Primary Objective:

To assess the efficacy of SpellBound's AR-enabled scavenger hunt to reduce the rate of additional inpatient opioid use in pediatric cancer patients who are chronic/tolerant opioid users undergoing surgery compared to a control non-AR game in a randomized controlled trial.

Secondary Objectives:

To assess the impact of AR versus non-AR control technology in pediatric oncology patients, including:

* Inpatient opioid use
* Average daily inpatient pain score
* Number of opioid requests during hospital stay
* Inpatient PedsQL (quality of life) questionnaire score
* Ambulation/"out of bed" movement
* Number days to discharge-ready status
* Patient experience assessed by satisfaction scores on questionnaire designed by MD Anderson Cancer Center Child Life team
* Outpatient opioid use reported at 30, 60, 90 days.
* Outpatient pain scores reported at 30, 60, 90 days
* Outpatient PedsQL scores reported at 30, 60, and 90 days
* Potential adverse events related to the use of AR (i.e., falls).

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
NCI-2022-08945 OTHER NCI- CTRP Clinical Trial Registry View